The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilar and Interchangeable Biologics Market Research Report 2024
Synopsis
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval. An interchangeable biosimilar is a biosimilar that meets additional requirements outlined by the law that allows for the FDA to approve biosimilar and interchangeable biosimilar medications. An interchangeable biosimilar product may be substituted for the original product without consulting the prescriber, much like how generic drugs are routinely substituted for brand name drugs.
The global Biosimilar and Interchangeable Biologics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Biosimilar and Interchangeable Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Biosimilar and Interchangeable Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Biosimilar and Interchangeable Biologics in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Biosimilar and Interchangeable Biologics include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Biosimilar and Interchangeable Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar and Interchangeable Biologics.
The Biosimilar and Interchangeable Biologics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar and Interchangeable Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar and Interchangeable Biologics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar and Interchangeable Biologics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval. An interchangeable biosimilar is a biosimilar that meets additional requirements outlined by the law that allows for the FDA to approve biosimilar and interchangeable biosimilar medications. An interchangeable biosimilar product may be substituted for the original product without consulting the prescriber, much like how generic drugs are routinely substituted for brand name drugs.
The global Biosimilar and Interchangeable Biologics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Biosimilar and Interchangeable Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Biosimilar and Interchangeable Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Biosimilar and Interchangeable Biologics in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Biosimilar and Interchangeable Biologics include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Biosimilar and Interchangeable Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar and Interchangeable Biologics.
The Biosimilar and Interchangeable Biologics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar and Interchangeable Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar and Interchangeable Biologics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar and Interchangeable Biologics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilar and Interchangeable Biologics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Market by Application
1.3.1 Global Biosimilar and Interchangeable Biologics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilar and Interchangeable Biologics Market Perspective (2019-2030)
2.2 Global Biosimilar and Interchangeable Biologics Growth Trends by Region
2.2.1 Global Biosimilar and Interchangeable Biologics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biosimilar and Interchangeable Biologics Historic Market Size by Region (2019-2024)
2.2.3 Biosimilar and Interchangeable Biologics Forecasted Market Size by Region (2025-2030)
2.3 Biosimilar and Interchangeable Biologics Market Dynamics
2.3.1 Biosimilar and Interchangeable Biologics Industry Trends
2.3.2 Biosimilar and Interchangeable Biologics Market Drivers
2.3.3 Biosimilar and Interchangeable Biologics Market Challenges
2.3.4 Biosimilar and Interchangeable Biologics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilar and Interchangeable Biologics Players by Revenue
3.1.1 Global Top Biosimilar and Interchangeable Biologics Players by Revenue (2019-2024)
3.1.2 Global Biosimilar and Interchangeable Biologics Revenue Market Share by Players (2019-2024)
3.2 Global Biosimilar and Interchangeable Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Biosimilar and Interchangeable Biologics Revenue
3.4 Global Biosimilar and Interchangeable Biologics Market Concentration Ratio
3.4.1 Global Biosimilar and Interchangeable Biologics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilar and Interchangeable Biologics Revenue in 2023
3.5 Global Key Players of Biosimilar and Interchangeable Biologics Head office and Area Served
3.6 Global Key Players of Biosimilar and Interchangeable Biologics, Product and Application
3.7 Global Key Players of Biosimilar and Interchangeable Biologics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilar and Interchangeable Biologics Breakdown Data by Type
4.1 Global Biosimilar and Interchangeable Biologics Historic Market Size by Type (2019-2024)
4.2 Global Biosimilar and Interchangeable Biologics Forecasted Market Size by Type (2025-2030)
5 Biosimilar and Interchangeable Biologics Breakdown Data by Application
5.1 Global Biosimilar and Interchangeable Biologics Historic Market Size by Application (2019-2024)
5.2 Global Biosimilar and Interchangeable Biologics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biosimilar and Interchangeable Biologics Market Size (2019-2030)
6.2 North America Biosimilar and Interchangeable Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biosimilar and Interchangeable Biologics Market Size by Country (2019-2024)
6.4 North America Biosimilar and Interchangeable Biologics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilar and Interchangeable Biologics Market Size (2019-2030)
7.2 Europe Biosimilar and Interchangeable Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biosimilar and Interchangeable Biologics Market Size by Country (2019-2024)
7.4 Europe Biosimilar and Interchangeable Biologics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar and Interchangeable Biologics Market Size (2019-2030)
8.2 Asia-Pacific Biosimilar and Interchangeable Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biosimilar and Interchangeable Biologics Market Size by Region (2019-2024)
8.4 Asia-Pacific Biosimilar and Interchangeable Biologics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilar and Interchangeable Biologics Market Size (2019-2030)
9.2 Latin America Biosimilar and Interchangeable Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biosimilar and Interchangeable Biologics Market Size by Country (2019-2024)
9.4 Latin America Biosimilar and Interchangeable Biologics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar and Interchangeable Biologics Market Size (2019-2030)
10.2 Middle East & Africa Biosimilar and Interchangeable Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biosimilar and Interchangeable Biologics Market Size by Country (2019-2024)
10.4 Middle East & Africa Biosimilar and Interchangeable Biologics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Biosimilar and Interchangeable Biologics Introduction
11.1.4 Roche Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Biosimilar and Interchangeable Biologics Introduction
11.2.4 Amgen Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Biosimilar and Interchangeable Biologics Introduction
11.3.4 AbbVie Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Biosimilar and Interchangeable Biologics Introduction
11.4.4 Sanofi Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Biosimilar and Interchangeable Biologics Introduction
11.5.4 Johnson & Johnson Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Biosimilar and Interchangeable Biologics Introduction
11.6.4 Pfizer Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Biosimilar and Interchangeable Biologics Introduction
11.7.4 Novo Nordisk Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Biosimilar and Interchangeable Biologics Introduction
11.8.4 Eli Lilly Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Biosimilar and Interchangeable Biologics Introduction
11.9.4 Novartis Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Biosimilar and Interchangeable Biologics Introduction
11.10.4 Merck Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.10.5 Merck Recent Development
11.11 Biogen
11.11.1 Biogen Company Details
11.11.2 Biogen Business Overview
11.11.3 Biogen Biosimilar and Interchangeable Biologics Introduction
11.11.4 Biogen Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.11.5 Biogen Recent Development
11.12 Celltrion
11.12.1 Celltrion Company Details
11.12.2 Celltrion Business Overview
11.12.3 Celltrion Biosimilar and Interchangeable Biologics Introduction
11.12.4 Celltrion Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.12.5 Celltrion Recent Development
11.13 Sobi
11.13.1 Sobi Company Details
11.13.2 Sobi Business Overview
11.13.3 Sobi Biosimilar and Interchangeable Biologics Introduction
11.13.4 Sobi Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.13.5 Sobi Recent Development
11.14 3SBIO
11.14.1 3SBIO Company Details
11.14.2 3SBIO Business Overview
11.14.3 3SBIO Biosimilar and Interchangeable Biologics Introduction
11.14.4 3SBIO Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.14.5 3SBIO Recent Development
11.15 Changchun High Tech
11.15.1 Changchun High Tech Company Details
11.15.2 Changchun High Tech Business Overview
11.15.3 Changchun High Tech Biosimilar and Interchangeable Biologics Introduction
11.15.4 Changchun High Tech Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.15.5 Changchun High Tech Recent Development
11.16 Kanghong Pharma
11.16.1 Kanghong Pharma Company Details
11.16.2 Kanghong Pharma Business Overview
11.16.3 Kanghong Pharma Biosimilar and Interchangeable Biologics Introduction
11.16.4 Kanghong Pharma Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.16.5 Kanghong Pharma Recent Development
11.17 Innovent Biologics
11.17.1 Innovent Biologics Company Details
11.17.2 Innovent Biologics Business Overview
11.17.3 Innovent Biologics Biosimilar and Interchangeable Biologics Introduction
11.17.4 Innovent Biologics Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.17.5 Innovent Biologics Recent Development
11.18 Gan&Lee
11.18.1 Gan&Lee Company Details
11.18.2 Gan&Lee Business Overview
11.18.3 Gan&Lee Biosimilar and Interchangeable Biologics Introduction
11.18.4 Gan&Lee Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.18.5 Gan&Lee Recent Development
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Details
11.19.2 Tonghua Dongbao Business Overview
11.19.3 Tonghua Dongbao Biosimilar and Interchangeable Biologics Introduction
11.19.4 Tonghua Dongbao Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.19.5 Tonghua Dongbao Recent Development
11.20 United Laboratory
11.20.1 United Laboratory Company Details
11.20.2 United Laboratory Business Overview
11.20.3 United Laboratory Biosimilar and Interchangeable Biologics Introduction
11.20.4 United Laboratory Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024)
11.20.5 United Laboratory Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Biosimilar and Interchangeable Biologics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Interferon
Table 4. Key Players of Insulin
Table 5. Key Players of Vaccines
Table 6. Key Players of Others
Table 7. Global Biosimilar and Interchangeable Biologics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Biosimilar and Interchangeable Biologics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Biosimilar and Interchangeable Biologics Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Biosimilar and Interchangeable Biologics Market Share by Region (2019-2024)
Table 11. Global Biosimilar and Interchangeable Biologics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Biosimilar and Interchangeable Biologics Market Share by Region (2025-2030)
Table 13. Biosimilar and Interchangeable Biologics Market Trends
Table 14. Biosimilar and Interchangeable Biologics Market Drivers
Table 15. Biosimilar and Interchangeable Biologics Market Challenges
Table 16. Biosimilar and Interchangeable Biologics Market Restraints
Table 17. Global Biosimilar and Interchangeable Biologics Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Biosimilar and Interchangeable Biologics Market Share by Players (2019-2024)
Table 19. Global Top Biosimilar and Interchangeable Biologics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar and Interchangeable Biologics as of 2023)
Table 20. Ranking of Global Top Biosimilar and Interchangeable Biologics Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Biosimilar and Interchangeable Biologics Revenue (CR5 and HHI) & (2019-2024)
Table 22. Global Key Players of Biosimilar and Interchangeable Biologics, Headquarters and Area Served
Table 23. Global Key Players of Biosimilar and Interchangeable Biologics, Product and Application
Table 24. Global Key Players of Biosimilar and Interchangeable Biologics, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Biosimilar and Interchangeable Biologics Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Biosimilar and Interchangeable Biologics Revenue Market Share by Type (2019-2024)
Table 28. Global Biosimilar and Interchangeable Biologics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Biosimilar and Interchangeable Biologics Revenue Market Share by Type (2025-2030)
Table 30. Global Biosimilar and Interchangeable Biologics Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Biosimilar and Interchangeable Biologics Revenue Market Share by Application (2019-2024)
Table 32. Global Biosimilar and Interchangeable Biologics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Biosimilar and Interchangeable Biologics Revenue Market Share by Application (2025-2030)
Table 34. North America Biosimilar and Interchangeable Biologics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Biosimilar and Interchangeable Biologics Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Biosimilar and Interchangeable Biologics Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Biosimilar and Interchangeable Biologics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Biosimilar and Interchangeable Biologics Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Biosimilar and Interchangeable Biologics Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Biosimilar and Interchangeable Biologics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Biosimilar and Interchangeable Biologics Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Biosimilar and Interchangeable Biologics Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Biosimilar and Interchangeable Biologics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Biosimilar and Interchangeable Biologics Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Biosimilar and Interchangeable Biologics Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Biosimilar and Interchangeable Biologics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Biosimilar and Interchangeable Biologics Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Biosimilar and Interchangeable Biologics Market Size by Country (2025-2030) & (US$ Million)
Table 49. Roche Company Details
Table 50. Roche Business Overview
Table 51. Roche Biosimilar and Interchangeable Biologics Product
Table 52. Roche Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 53. Roche Recent Development
Table 54. Amgen Company Details
Table 55. Amgen Business Overview
Table 56. Amgen Biosimilar and Interchangeable Biologics Product
Table 57. Amgen Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 58. Amgen Recent Development
Table 59. AbbVie Company Details
Table 60. AbbVie Business Overview
Table 61. AbbVie Biosimilar and Interchangeable Biologics Product
Table 62. AbbVie Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 63. AbbVie Recent Development
Table 64. Sanofi Company Details
Table 65. Sanofi Business Overview
Table 66. Sanofi Biosimilar and Interchangeable Biologics Product
Table 67. Sanofi Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 68. Sanofi Recent Development
Table 69. Johnson & Johnson Company Details
Table 70. Johnson & Johnson Business Overview
Table 71. Johnson & Johnson Biosimilar and Interchangeable Biologics Product
Table 72. Johnson & Johnson Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 73. Johnson & Johnson Recent Development
Table 74. Pfizer Company Details
Table 75. Pfizer Business Overview
Table 76. Pfizer Biosimilar and Interchangeable Biologics Product
Table 77. Pfizer Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 78. Pfizer Recent Development
Table 79. Novo Nordisk Company Details
Table 80. Novo Nordisk Business Overview
Table 81. Novo Nordisk Biosimilar and Interchangeable Biologics Product
Table 82. Novo Nordisk Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 83. Novo Nordisk Recent Development
Table 84. Eli Lilly Company Details
Table 85. Eli Lilly Business Overview
Table 86. Eli Lilly Biosimilar and Interchangeable Biologics Product
Table 87. Eli Lilly Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 88. Eli Lilly Recent Development
Table 89. Novartis Company Details
Table 90. Novartis Business Overview
Table 91. Novartis Biosimilar and Interchangeable Biologics Product
Table 92. Novartis Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 93. Novartis Recent Development
Table 94. Merck Company Details
Table 95. Merck Business Overview
Table 96. Merck Biosimilar and Interchangeable Biologics Product
Table 97. Merck Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 98. Merck Recent Development
Table 99. Biogen Company Details
Table 100. Biogen Business Overview
Table 101. Biogen Biosimilar and Interchangeable Biologics Product
Table 102. Biogen Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 103. Biogen Recent Development
Table 104. Celltrion Company Details
Table 105. Celltrion Business Overview
Table 106. Celltrion Biosimilar and Interchangeable Biologics Product
Table 107. Celltrion Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 108. Celltrion Recent Development
Table 109. Sobi Company Details
Table 110. Sobi Business Overview
Table 111. Sobi Biosimilar and Interchangeable Biologics Product
Table 112. Sobi Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 113. Sobi Recent Development
Table 114. 3SBIO Company Details
Table 115. 3SBIO Business Overview
Table 116. 3SBIO Biosimilar and Interchangeable Biologics Product
Table 117. 3SBIO Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 118. 3SBIO Recent Development
Table 119. Changchun High Tech Company Details
Table 120. Changchun High Tech Business Overview
Table 121. Changchun High Tech Biosimilar and Interchangeable Biologics Product
Table 122. Changchun High Tech Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 123. Changchun High Tech Recent Development
Table 124. Kanghong Pharma Company Details
Table 125. Kanghong Pharma Business Overview
Table 126. Kanghong Pharma Biosimilar and Interchangeable Biologics Product
Table 127. Kanghong Pharma Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 128. Kanghong Pharma Recent Development
Table 129. Innovent Biologics Company Details
Table 130. Innovent Biologics Business Overview
Table 131. Innovent Biologics Biosimilar and Interchangeable Biologics Product
Table 132. Innovent Biologics Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 133. Innovent Biologics Recent Development
Table 134. Gan&Lee Company Details
Table 135. Gan&Lee Business Overview
Table 136. Gan&Lee Biosimilar and Interchangeable Biologics Product
Table 137. Gan&Lee Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 138. Gan&Lee Recent Development
Table 139. Tonghua Dongbao Company Details
Table 140. Tonghua Dongbao Business Overview
Table 141. Tonghua Dongbao Biosimilar and Interchangeable Biologics Product
Table 142. Tonghua Dongbao Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 143. Tonghua Dongbao Recent Development
Table 144. United Laboratory Company Details
Table 145. United Laboratory Business Overview
Table 146. United Laboratory Biosimilar and Interchangeable Biologics Product
Table 147. United Laboratory Revenue in Biosimilar and Interchangeable Biologics Business (2019-2024) & (US$ Million)
Table 148. United Laboratory Recent Development
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
Table 152. Authors List of This Report
List of Figures
Figure 1. Biosimilar and Interchangeable Biologics Picture
Figure 2. Global Biosimilar and Interchangeable Biologics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Biosimilar and Interchangeable Biologics Market Share by Type: 2023 VS 2030
Figure 4. Monoclonal Antibodies Features
Figure 5. Interferon Features
Figure 6. Insulin Features
Figure 7. Vaccines Features
Figure 8. Others Features
Figure 9. Global Biosimilar and Interchangeable Biologics Market Size by Application (2024-2030) & (US$ Million)
Figure 10. Global Biosimilar and Interchangeable Biologics Market Share by Application: 2023 VS 2030
Figure 11. Hospital Case Studies
Figure 12. Retail Pharmacy Case Studies
Figure 13. Other Case Studies
Figure 14. Biosimilar and Interchangeable Biologics Report Years Considered
Figure 15. Global Biosimilar and Interchangeable Biologics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Biosimilar and Interchangeable Biologics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Biosimilar and Interchangeable Biologics Market Share by Region: 2023 VS 2030
Figure 18. Global Biosimilar and Interchangeable Biologics Market Share by Players in 2023
Figure 19. Global Top Biosimilar and Interchangeable Biologics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar and Interchangeable Biologics as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Biosimilar and Interchangeable Biologics Revenue in 2023
Figure 21. North America Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Biosimilar and Interchangeable Biologics Market Share by Country (2019-2030)
Figure 23. United States Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Biosimilar and Interchangeable Biologics Market Share by Country (2019-2030)
Figure 27. Germany Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Biosimilar and Interchangeable Biologics Market Share by Region (2019-2030)
Figure 35. China Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Biosimilar and Interchangeable Biologics Market Share by Country (2019-2030)
Figure 43. Mexico Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Biosimilar and Interchangeable Biologics Market Share by Country (2019-2030)
Figure 47. Turkey Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. UAE Biosimilar and Interchangeable Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Roche Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 51. Amgen Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 52. AbbVie Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 53. Sanofi Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 54. Johnson & Johnson Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 55. Pfizer Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 56. Novo Nordisk Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 57. Eli Lilly Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 58. Novartis Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 59. Merck Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 60. Biogen Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 61. Celltrion Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 62. Sobi Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 63. 3SBIO Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 64. Changchun High Tech Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 65. Kanghong Pharma Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 66. Innovent Biologics Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 67. Gan&Lee Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 68. Tonghua Dongbao Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 69. United Laboratory Revenue Growth Rate in Biosimilar and Interchangeable Biologics Business (2019-2024)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
